HLA
KRTX

Hamilton Lane Advisors’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Hamilton Lane Advisors’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,061
Closed -$1.1M – 53
2023
Q2 		$1.1M Sell
5,061
-9,222
-65% -$1.98M 0.48% 30
2023
Q1 		$2.59M Sell
14,283
-49,807
-78% -$9.53M 0.87% 16
2022
Q4 		$12.6M Sell
64,090
-13,196
-17% -$2.83M 4.55% 5
2022
Q3 		$17.4M Buy
+77,286
New +$15.6M 6.36% 4

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Hamilton Lane Advisors's KRTX Position: Q3 2023 in Review

Hamilton Lane Advisors sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q3 2023, closing a stake of 5,061 shares — an estimated $1.1M sold.

Hamilton Lane Advisors first reported a position in KRTX in Q3 2022 and held it in 4 quarters. The position peaked at $17.4M in Q3 2022. 256 funds tracked by Wall St. Rank hold KRTX as of Q3 2023.

  • Hamilton Lane Advisors reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Hamilton Lane Advisors sold 5,061 Karuna Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $1.1M.
  • Hamilton Lane Advisors first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2022 and held it in 4 quarters.
  • Hamilton Lane Advisors's Karuna Therapeutics, Inc. Common Stock position peaked at $17.4M in Q3 2022.
  • 256 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Hamilton Lane Advisors's 13F filing for Q3 2023, filed 7 Nov 2023.